Omnicell Buys PSG’s 340B Line of Business, the Latest in a Trend of 340B TPA
Updated: Sep 29, 2020
Omnicell is already a leading provider of prescription drug chain products and services. Now, they've purchased PSG's 340B line of business at a whopping $225 million for the 340B link.
According to Randall Lipps, (chairman, president, CEO, and founder of Omnicell), this deal will bring Omnicell "even closer to their long-term goals of an autonomous pharmacy".
What does this mean for Omnicell long term? What happens to PSG's management and operations team?
Check out 340B reports recent article by Tom Mirga here for more on this deal, and how it affects your covered entity.